EUPRAXIA PHARMACEUTICALS INC.
For the period ended Dec 31, 2024. Filed Mar 20, 2025.
View on SEC.govAbout this filing
The yearly report of certain Canadian companies, filed under a joint US and Canadian system. It is the main yearly account these companies give US investors, largely as filed in Canada.
FY2024 · Filed Mar 20, 2025
Use the contents to explore the available documents and sections.
EPRX$6.89+4.4%Stored close · as of Nov 6, 2026
Contents
EX-99.1 · Funding
Funding
The Company must provide appropriate funding, as determined by the Audit Committee, for the payment of:
| a. | compensation to any external auditor engaged for the purpose of preparing or issuing an audit report or performing other audit, review or attest services for the Company; |
|---|
| b. | compensation to any advisers engaged by the Audit Committee; and |
|---|
| c. | ordinary administrative expenses of the Audit Committee that are necessary or appropriate in carrying out its duties. |
|---|
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.